The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
MUNDESINE® (forodesine hydrochloride) approved by Japan’s MHLW for relapsed or refractory Peripheral T-Cell Lymphoma
On 30th March 2017, the Japanese Ministry of Health, Labor and Welfare (MHLW) approved MUNDESINE® (forodesine hydrochloride) for the treatment of Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL).
Mundipharma’s MUNDESINE® is an orally administered Purine Nucleoside Phosphorylase (PNP) inhibitor, and this approval is the first in the world for this type of agent. PNP inhibition results in increased levels of 2'-deoxyguanosine and buildup of intracellular deoxyguanosine 5'-triphosphate, initiating apoptosis.2
The compound is the first oral monotherapy for this indication and also holds Orphan Drug status in Japan. The approval is based on successful clinical trials.
References